(Q42703579)

5 November 2017

title

Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation (English)

1 reference

5 November 2017

0 references

hepatocellular carcinoma

1 reference

8

1 reference

5 November 2017

Hongchi Jiang

7

0 references

author name string

Bo Zhai

1

1 reference

5 November 2017

Xian Jiang

2

1 reference

5 November 2017

Changjun He

3

1 reference

5 November 2017

Dali Zhao

4

1 reference

5 November 2017

Lixin Ma

5

1 reference

5 November 2017

Lishan Xu

6

1 reference

5 November 2017

language of work or name

1 reference

22 November 2014

1 reference

5 November 2017

1 reference

5 November 2017

volume

36

1 reference

5 November 2017

issue

4

1 reference

5 November 2017

page(s)

2323-2334

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-014-2839-3

5 November 2017

exact match

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Systemic treatment of hepatocellular carcinoma: dawn of a new era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Introduction: the history of arsenic trioxide in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Arsenic trioxide decreases AKT protein in a caspase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the adaptive antioxidant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Molecular mechanisms of sorafenib action in liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Cell cycle, CDKs and cancer: a changing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine-induced progressive liver carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2839-3

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

21 January 2018

1 reference

12 December 2020

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways

1 reference

12 December 2020

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2

1 reference

12 December 2020

Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells

1 reference

12 December 2020

Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells

1 reference

12 December 2020

10.1007/S13277-014-2839-3

Identifiers

DOI

1 reference

Dimensions Publication ID

5 November 2017

1043381417

0 references

1 reference